Target Information

Target General Infomation
Target ID
T61484
Former ID
TTDI01946
Target Name
Chymotrypsin
Target Type
Clinical Trial
Disease Attention deficit hyperactivity disorder; Autism [ICD9:314, 299; ICD10: F90, F84.0]
Cancer [ICD9: 140-229; ICD10: C00-C96]
Cystic fibrosis [ICD9: 277; ICD10: E84]
Pancreatic disease [ICD10: K85-K86]
BioChemical Class
Peptidase
EC Number
EC 3.4.21.1
Drugs and Mode of Action
Drug(s) Pancrecarb Drug Info NDA filed Pancreatic disease [550604]
CM-AT Drug Info Phase 3 Attention deficit hyperactivity disorder; Autism [522637]
Liprotamase Drug Info Phase 3 Cystic fibrosis [522063]
Modulator CM-AT Drug Info [525377]
JBP-1 Drug Info [549592], [550162]
Liprotamase Drug Info [549848]
Pancrecarb Drug Info [549592], [550162]
POP-1 Drug Info [549592], [550162]
References
Ref 522063ClinicalTrials.gov (NCT00500084) Phase III ALTU-135 CP Safety Trial. U.S. National Institutes of Health.
Ref 522637ClinicalTrials.gov (NCT00881452) A Trial of CM-AT in Children With Autism. U.S. National Institutes of Health.
Ref 550604Clinical pipeline report, company report or official report of Digestive Care.
Ref 525377Drugmakers dance with autism. Nat Biotechnol. 2010 Aug;28(8):772-4. doi: 10.1038/nbt0810-772.
Ref 549592US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
Ref 549848Clinical pipeline report, company report or official report of Anthera Pharmaceuticals.
Ref 550162EP patent application no. 2490711, A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.